Beta Bionics vs Ceribell
Beta Bionics reported revenue of $100 million in fiscal 2025, about the same as Ceribell's $89 million in fiscal 2025. Beta Bionics' revenue grew 53.9% in its latest year, and Ceribell's grew 36.1%. Beta Bionics had an operating margin of -71.5%, against -65.6% at Ceribell. Free cash flow was −$56 million at Beta Bionics and −$42 million at Ceribell.
Side by side
| Beta Bionics | Ceribell | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $100M | $89M |
| Revenue growth | 53.9% | 36.1% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 55.4% | 87.9% |
| Operating margin | −71.5% | −65.6% |
| Net margin | −73.0% | −60.0% |
| Free cash flow | −$56M | −$42M |
| Free cash flow margin | −56.1% | −46.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 536.7% | 205.8% |
| Last close | $16.42 | $26.14 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Beta BionicsCeribell
Operating margin
Percent of revenue
Beta BionicsCeribell
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Beta BionicsCeribell
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Beta Bionics and Ceribell pages.